(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 November 2007 (01.11.2007)

PCT

(10) International Publication Number
WO 2007/124299 A3

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2007/066757

(22) International Filing Date: 17 April 2007 (17.04.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/794,011 21 April 2006 (21.04.2006) US

(71) Applicants *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). **XOMA TECHNOLOGY LTD.** [US/US]; 2910 Seventh Street, Berkley, CA 94701 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LU, Xiaofeng** [CN/US]; Novartis Vaccines And Diagnostics, Inc., P.o.box 8097, Emeryville, CA 94662-8097 (US). **CHEN, Bao-Lu** [US/US]; Novartis Vaccines And Diagnostics, Inc., P.o.box 8097, Emeryville, CA 94662-8097 (US). **ARAYA, Kidisti** [US/US]; Novartis Vaccines And Diagnostics, Inc., P.o. Box 8097, Emeryville, CA 94662-8097 (US). **OKHAMAFE, Augustus** [US/US]; Novartis Vaccines And Diagnostics, Inc., P.o. Box 8097, Emeryville, CA 94662-8097 (US).

(74) Agents: **HERNRY, Leslie, T.** et al.; ALSTON & BIRD LLP, Bank Of America Plaza, 101 South Tryon Street, Suite 4000, Charlotte, NC 28280-4000 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(88) Date of publication of the international search report:
3 January 2008

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTAGONIST ANTI-CD40 ANTIBODY PHARMACEUTICAL COMPOSITIONS



(57) Abstract: Stable liquid pharmaceutical compositions comprising an antagonist anti- CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody -containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.

WO 2007/124299 A3